RESUMEN
BACKGROUND AND PURPOSE: Multiple studies have demonstrated evidence of sex differences in patients with MS, including differences in disease progression, cognitive decline, and biologic markers. This study used functional connectivity MRI to investigate sex differences in the strength of functional connectivity of the default mode network in patients with MS and healthy control subjects. MATERIALS AND METHODS: A total of 16 men and 16 women with MS and 32 age- and sex-matched healthy control subjects underwent a whole-brain resting-state functional connectivity MRI scan. A group-based seed in the posterior cingulate was used to create whole-brain correlation maps. A 2 × 2 ANOVA was used to assess whether disease status and sex affected the strength of connectivity to the posterior cingulate. RESULTS: Patients with MS showed significantly stronger connectivity from the posterior cingulate to the bilateral medial frontal gyri, the left ventral anterior cingulate, the right putamen, and the left middle temporal gyrus (P < .0005). In the left dorsal lateral prefrontal cortex, female patients showed significantly stronger connectivity to the posterior cingulate cortex compared with female control subjects (P = 3 × 10(4)), and male control subjects showed stronger posterior cingulate cortex-left dorsal lateral prefrontal cortex connectivity in comparison to female control subjects (P = .002). Male patients showed significantly weaker connectivity to the caudate compared with female patients (P = .004). CONCLUSIONS: Disease status and sex interact to produce differences in the strength of functional connectivity from the posterior cingulate to the caudate and the left dorsal lateral prefrontal cortex.
Asunto(s)
Mapeo Encefálico/métodos , Encéfalo/fisiopatología , Conectoma/métodos , Imagen por Resonancia Magnética/métodos , Esclerosis Múltiple/fisiopatología , Red Nerviosa/fisiopatología , Adulto , Encéfalo/patología , Femenino , Humanos , Masculino , Esclerosis Múltiple/patología , Red Nerviosa/patología , Vías Nerviosas/patología , Vías Nerviosas/fisiopatología , Descanso , Factores SexualesRESUMEN
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of unknown etiology that can involve all parts of the central nervous system and is unique to humans. Therefore, analysis of human tissue is critical for generating hypotheses for testing in animal or in vitro models and for validating research findings from these experimental models. This article reviews data on demyelination and remyelination in the cerebral cortex. We show that research on cerebral cortical demyelination and remyelination in appropriately processed postmortem MS tissues provides innovative approaches for developing hypotheses for studies on the pathogenesis MS lesions including identification of targets for therapy at early stages of the disease.
Asunto(s)
Corteza Cerebral/patología , Esclerosis Múltiple/patología , Proteínas de la Mielina/metabolismo , Vaina de Mielina/patología , Animales , Modelos Animales de Enfermedad , HumanosRESUMEN
OBJECTIVE: To characterize pathologic changes in the cerebral cortex of patients with multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML). METHODS: Autopsy brain tissue was obtained from 13 patients with PML, 4 patients with MS, 2 patients with HIV encephalopathy, and 1 subject without neurologic pathology. Immunohistochemistry for myelin proteins, inflammatory cells, and neurofilaments was performed to evaluate the distribution of cortical lesions, their inflammatory activity, and neuritic pathology. Confocal microscopy was applied to examine pathologic changes in neurites in PML cortex. RESULTS: Leukocortical, intracortical, and subpial patterns of cortical demyelination were represented in MS brain tissue. In PML brain tissue intracortical and leukocortical but not subpial lesions were observed. Cortical lesions in PML and MS contained fewer inflammatory cells than demyelinated areas in the white matter. Neuritic pathology in cortical PML lesions was represented by dystrophic and transected neurites. Pathologic modifications in neuritic processes in PML were more evident in highly inflamed white matter than in gray matter areas of demyelination, reminiscent of previous reports of neuritic pathology in MS. JC virus-infected cells were associated with PML white matter, leukocortical and intracortical lesions. CONCLUSIONS: Cortical pathology represents a distinct feature of progressive multifocal leukoencephalopathy. Similarities and differences with regard to multiple sclerosis cortical pathology were noted and may be informative regarding the pathogenesis of both disorders.
Asunto(s)
Corteza Cerebral/patología , Leucoencefalopatía Multifocal Progresiva/patología , Esclerosis Múltiple/patología , Fibras Nerviosas Mielínicas/patología , Complejo SIDA Demencia/patología , Adulto , Anciano , Recuento de Células , Progresión de la Enfermedad , Femenino , Humanos , Inmunohistoquímica , Virus JC/aislamiento & purificación , Leucoencefalopatía Multifocal Progresiva/virología , Linfocitos/patología , Macrófagos/patología , Masculino , Microglía/patología , Persona de Mediana Edad , Neuritas/patología , Neuronas/patologíaRESUMEN
Fragile X-associated tremor/ataxia syndrome (FXTAS) is an adult-onset neurodegenerative disorder that affects carriers, principally males, of premutation alleles (55-200 CGG repeats) of the fragile X mental retardation 1 (FMR1) gene. Clinical features of FXTAS include progressive intention tremor and gait ataxia, accompanied by characteristic white matter abnormalities on MRI. The neuropathological hallmark of FXTAS is an intranuclear inclusion, present in both neurons and astrocytes throughout the CNS. Prior to the current work, the nature of the associations between inclusion loads and molecular measures (e.g. CGG repeat) was not defined. Post-mortem brain and spinal cord tissue has been examined for gross and microscopic pathology in a series of 11 FXTAS cases (males, age 67-87 years at the time of death). Quantitative counts of inclusion numbers were performed in various brain regions in both neurons and astrocytes. Inclusion counts were compared with specific molecular (CGG repeat, FMR1 mRNA level) and clinical (age of onset, age of death) parameters. In the current series, the three most prominent neuropathological characteristics are (i) significant cerebral and cerebellar white matter disease, (ii) associated astrocytic pathology with dramatically enlarged inclusion-bearing astrocytes prominent in cerebral white matter and (iii) the presence of intranuclear inclusions in both brain and spinal cord. The pattern of white matter pathology is distinct from that associated with hypertensive vascular disease and other diseases of white matter. Spongiosis was present in the middle cerebellar peduncles in seven of the eight cases in which those tissues were available for study. There is inclusion formation in cranial nerve nucleus XII and in autonomic neurons of the spinal cord. The most striking finding is the highly significant association between the number of CGG repeats and the numbers of intranuclear inclusions in both neurons and astrocytes, indicating that the CGG repeat is a powerful predictor of neurological involvement in males, both clinically (age of death) and neuropathologically (number of inclusions).
Asunto(s)
Astrocitos/ultraestructura , Ataxia/patología , Síndrome del Cromosoma X Frágil/patología , Cuerpos de Inclusión Intranucleares/ultraestructura , Neuronas/ultraestructura , Temblor/patología , Edad de Inicio , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Ataxia/genética , Encéfalo/patología , Estudios de Casos y Controles , Recuento de Células , Proteína de la Discapacidad Intelectual del Síndrome del Cromosoma X Frágil/genética , Síndrome del Cromosoma X Frágil/genética , Humanos , Masculino , Médula Espinal/patología , Temblor/genética , Expansión de Repetición de TrinucleótidoRESUMEN
Central nervous system myelin is a specialized structure produced by oligodendrocytes that ensheaths axons, allowing rapid and efficient saltatory conduction of action potentials. Many disorders promote damage to and eventual loss of the myelin sheath, which often results in significant neurological morbidity. However, little is known about the fundamental mechanisms that initiate myelin damage, with the assumption being that its fate follows that of the parent oligodendrocyte. Here we show that NMDA (N-methyl-d-aspartate) glutamate receptors mediate Ca2+ accumulation in central myelin in response to chemical ischaemia in vitro. Using two-photon microscopy, we imaged fluorescence of the Ca2+ indicator X-rhod-1 loaded into oligodendrocytes and the cytoplasmic compartment of the myelin sheath in adult rat optic nerves. The AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid)/kainate receptor antagonist NBQX completely blocked the ischaemic Ca2+ increase in oligodendroglial cell bodies, but only modestly reduced the Ca2+ increase in myelin. In contrast, the Ca2+ increase in myelin was abolished by broad-spectrum NMDA receptor antagonists (MK-801, 7-chlorokynurenic acid, d-AP5), but not by more selective blockers of NR2A and NR2B subunit-containing receptors (NVP-AAM077 and ifenprodil). In vitro ischaemia causes ultrastructural damage to both axon cylinders and myelin. NMDA receptor antagonism greatly reduced the damage to myelin. NR1, NR2 and NR3 subunits were detected in myelin by immunohistochemistry and immunoprecipitation, indicating that all necessary subunits are present for the formation of functional NMDA receptors. Our data show that the mature myelin sheath can respond independently to injurious stimuli. Given that axons are known to release glutamate, our finding that the Ca2+ increase was mediated in large part by activation of myelinic NMDA receptors suggests a new mechanism of axo-myelinic signalling. Such a mechanism may represent a potentially important therapeutic target in disorders in which demyelination is a prominent feature, such as multiple sclerosis, neurotrauma, infections (for example, HIV encephalomyelopathy) and aspects of ischaemic brain injury.
Asunto(s)
Calcio/metabolismo , Isquemia/metabolismo , Isquemia/patología , Vaina de Mielina/metabolismo , Receptores de N-Metil-D-Aspartato/metabolismo , Animales , Señalización del Calcio/efectos de los fármacos , Antagonistas de Aminoácidos Excitadores/farmacología , Vaina de Mielina/efectos de los fármacos , Oligodendroglía/efectos de los fármacos , Oligodendroglía/metabolismo , Nervio Óptico/citología , Nervio Óptico/patología , Ratas , Ratas Long-Evans , Receptores de Glutamato/metabolismo , Receptores de N-Metil-D-Aspartato/antagonistas & inhibidoresRESUMEN
The present study examined the extent and distribution of lymphocyte infiltration in demyelinated lesions in the cerebral cortex of multiple sclerosis (MS) patients. Tissue sections from the brain of 10 MS patients and five patients without neurological disease were double labeled for myelin basic protein and the lymphocyte markers CD3, CD4, CD8, CD45RO, and CD20. The highest density of CD3-positive T cells was found in MS white matter lesions (40.4/10 high power fields (hpf)). Fewer T cells were detected in cortical lesions that extended through both white and gray matter (12.1/10 hpf; P < 0.001). The lowest number of T cells was detected in intracortical demyelinated lesions (1.1/10 hpf). This was equal to the lymphocyte density in nondemyelinated cerebral cortex within the same tissue block (1.1/10 hpf) or cerebral cortex in control brains (1.8/10 hpf). A similar distribution was found using the CD4, CD8, and CD45RO markers. CD20-positive B cells were scarce in all specimens examined. These data indicate that areas of intracortical demyelination in chronic MS are not associated with an increased number of lymphocytes, or an altered distribution of lymphocyte subsets, when compared with control areas in MS and control patients. This finding indicates that the extent of lymphocyte infiltration in MS lesions is dependent on lesion location.
Asunto(s)
Corteza Cerebral/inmunología , Corteza Cerebral/patología , Subgrupos Linfocitarios/patología , Esclerosis Múltiple/inmunología , Esclerosis Múltiple/patología , Adulto , Anciano , Antígenos CD20/análisis , Linfocitos B/química , Linfocitos B/patología , Biomarcadores , Complejo CD3/análisis , Antígenos CD4/análisis , Antígenos CD8/análisis , Femenino , Humanos , Antígenos Comunes de Leucocito/análisis , Subgrupos Linfocitarios/química , Masculino , Persona de Mediana Edad , Fibras Nerviosas/inmunología , Fibras Nerviosas/patología , Linfocitos T/química , Linfocitos T/patologíaRESUMEN
Axonal degeneration has been identified as the major determinant of irreversible neurological disability in patients with multiple sclerosis (MS). Axonal injury begins at disease onset and correlates with the degree of inflammation within lesions, indicating that inflammatory demyelination influences axon pathology during relapsing-remitting MS (RR-MS). This axonal loss remains clinically silent for many years, and irreversible neurological disability develops when a threshold of axonal loss is reached and compensatory CNS resources are exhausted. Experimental support for this view-the axonal hypothesis-is provided by data from various animal models with primary myelin or axonal pathology, and from pathological or magnetic resonance studies on MS patients. In mice with experimental autoimmune encephalomyelitis (EAE), 15-30% of spinal cord axons can be lost before permanent ambulatory impairment occurs. During secondary progressive MS (SP-MS), chronically demyelinated axons may degenerate due to lack of myelin-derived trophic support. In addition, we hypothesize that reduced trophic support from damaged targets or degeneration of efferent fibers may trigger preprogrammed neurodegenerative mechanisms. The concept of MS as an inflammatory neurodegenerative disease has important clinical implications regarding therapeutic approaches, monitoring of patients, and the development of neuroprotective treatment strategies.
Asunto(s)
Axones/patología , Esclerosis Múltiple/patología , Animales , Progresión de la Enfermedad , Encefalomielitis Autoinmune Experimental/patología , Encefalomielitis Autoinmune Experimental/fisiopatología , Humanos , Ratones , Esclerosis Múltiple/clasificación , Esclerosis Múltiple/fisiopatología , Degeneración Nerviosa/patología , Degeneración Nerviosa/fisiopatología , Índice de Severidad de la Enfermedad , Médula Espinal/patología , Médula Espinal/fisiopatologíaRESUMEN
BACKGROUND: Brain imaging studies detect abnormalities in normal-appearing white matter in patients with MS. OBJECTIVE: To investigate the histopathologic basis for these changes in autopsy tissue from a patient with MS with 9 months' disease duration and a terminal brain stem lesion. METHODS: The brain stem and spinal cord were analyzed ultrastructurally and immunocytochemically for axons, myelin, and activated microglia/macrophages. RESULTS: Pathologic findings were consistent with a terminal inflammatory demyelinated lesion at the cervicomedullary junction. The ventral spinal cord column, containing descending tracts, exhibited 22% axonal loss at segment C7, but grossly normal immunostaining for myelin. Confocal and electron microscopy revealed myelin sheaths without axonal content and initial stages of myelin degradation by activated microglia/macrophages among intact myelinated axons. Axonal number and appearance was normal in ascending sensory tracts. CONCLUSIONS: These studies confirm axonal degeneration in the absence of myelin loss as one histopathologic correlate to abnormal MR findings in patients with MS.
Asunto(s)
Axones/patología , Esclerosis Múltiple Recurrente-Remitente/patología , Enfermedad Aguda , Adulto , Axones/ultraestructura , Tronco Encefálico/patología , Resultado Fatal , Humanos , Masculino , Microscopía Electrónica , Vaina de Mielina/patología , Vaina de Mielina/ultraestructura , Médula Espinal/patologíaRESUMEN
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that causes motor, sensory, and cognitive deficits. The present study characterized demyelinated lesions in the cerebral cortex of MS patients. One hundred twelve cortical lesions were identified in 110 tissue blocks from 50 MS patients. Three patterns of cortical demyelination were identified: Type I lesions were contiguous with subcortical white matter lesions; Type II lesions were small, confined to the cortex, and often perivascular; Type III lesions extended from the pial surface to cortical layer 3 or 4. Inflammation and neuronal pathology were studied in tissue from 8 and 7 patients, respectively. Compared to white matter lesions, cortical lesions contained 13 times fewer CD3-positive lymphocytes (195 vs 2,596/mm3 of tissue) and 6 times fewer CD68-positive microglia/macrophages (11,948 vs 67,956/mm3 of tissue). Transected neurites (both axons and dendrites) occurred at a density of 4,119/mm3 in active cortical lesions, 1,107/mm3 in chronic active cortical lesions, 25/mm3 in chronic inactive cortical lesions, 8/mm3 in myelinated MS cortex, and 1/mm3 in control cortex. In active and chronic active cortical lesions, activated microglia closely apposed and ensheathed apical dendrites, neurites, and neuronal perikarya. In addition, apoptotic neurons were increased significantly in demyelinated cortex compared to myelinated cortex. These data support the hypothesis that demyelination, axonal transection, dendritic transection, and apoptotic loss of neurons in the cerebral cortex contribute to neurological dysfunction in MS patients.
Asunto(s)
Apoptosis/inmunología , Corteza Cerebral/patología , Enfermedades Desmielinizantes/patología , Esclerosis Múltiple/patología , Neuritas/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Antígenos CD/inmunología , Antígenos de Diferenciación Mielomonocítica/inmunología , Complejo CD3/inmunología , Corteza Cerebral/inmunología , Enfermedades Desmielinizantes/inmunología , Femenino , Genes MHC Clase II/inmunología , Humanos , Masculino , Persona de Mediana Edad , Esclerosis Múltiple/inmunología , Neuronas/patología , Estudios Retrospectivos , Estadísticas no ParamétricasRESUMEN
N-acetyl aspartate (NAA), a putative marker of neuronal injury, can be measured non-invasively in patients by magnetic resonance spectroscopy (MRS). Interpretation of in vivo MRS data, however, requires neuropathological correlates to NAA alterations using autopsy or biopsy material. Since detailed hydrolysis data is lacking, NAA and the related dipeptide N-acetyl aspartylglutamate (NAAG) were quantified by high performance liquid chromatography (HPLC) in different rat CNS regions over 24 h postmortem. Both molecules decreased rapidly 1-4 h postmortem, and subsequently slower with time. The average reduction at 24 h was 46% and 38% for NAA and NAAG respectively. The NAA reduction was proportionally smaller in cortical areas (34-37%) compared to more caudal regions (54-58%). An exception was the optic nerve, a pure white matter tract, where NAA and NAAG hydrolysis was slower. The NAA/NAAG ratio remained relatively constant, but exhibited marked regional differences. The data show a significant postmortem degradation of NAA and NAAG that needs to be considered when these compounds are studied ex-vivo.
Asunto(s)
Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Sistema Nervioso Central/metabolismo , Dipéptidos/metabolismo , Cambios Post Mortem , Animales , Cromatografía Líquida de Alta Presión , Hidrólisis , Masculino , Ratas , Ratas Sprague-Dawley , Distribución TisularRESUMEN
Renewed interest in axonal injury in multiple sclerosis has significantly shifted the focus of research into this disease toward neurodegeneration. During the past year magnetic resonance and morphologic studies have continued to confirm and extend the concept that axonal transection begins at disease onset, and that cumulative axonal loss provides the pathologic substrate for the progressive disability that most long-term MS patients experience. Although inflammation and chronic demyelination are probable causes of axonal transection, little is known about the molecular mechanisms that are involved. The view that MS can also be considered an inflammatory neurodegenerative disease has important clinical implications for therapeutic approaches, monitoring of patients, and future treatment strategies.
Asunto(s)
Axones/patología , Imagen por Resonancia Magnética , Espectroscopía de Resonancia Magnética , Esclerosis Múltiple/patología , Degeneración Nerviosa/patología , Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Atrofia , Encéfalo/patología , Humanos , Esclerosis Múltiple/diagnóstico , Neuronas/patologíaRESUMEN
Miller-Fisher syndrome is an autoimmune neuropathy characterized by ataxia, areflexia and ophthalmoplegia, and in the majority of cases the presence of high titres of anti-GQ1b ganglioside antibodies. In an ex vivo model, human and mouse anti-GQ1b antibodies have been shown previously to induce a complement-dependent alpha-latrotoxin-like effect on the murine motor endplate, i.e. they bring about massive quantal release of acetylcholine and eventually block neuromuscular transmission. Using immunofluorescence microscopy with image analysis, we show here that the late stages of this electrophysiological effect temporally coincide with the loss of heavy neurofilament (200 kDa) and type III beta-tubulin immunostaining and structural breakdown of the nerve terminal, as demonstrated by electron microscopy. Ultrastructurally, axon terminals were disorganized, depleted of vesicles, and subdivided by the infiltrating processes of capping Schwann cells. These findings provide clear pathological evidence to support a role for anti-ganglioside antibodies in mediating nerve terminal injury and further advance the view that this site may be of importance as a target in some human neuropathies.
Asunto(s)
Autoanticuerpos/efectos adversos , Activación de Complemento/inmunología , Gangliósidos/inmunología , Síndrome de Miller Fisher/inmunología , Unión Neuromuscular/inmunología , Fosfatasa Alcalina/farmacología , Animales , Modelos Animales de Enfermedad , Gangliósidos/antagonistas & inhibidores , Procesamiento de Imagen Asistido por Computador , Técnicas In Vitro , Masculino , Ratones , Microscopía Electrónica , Microscopía Fluorescente , Síndrome de Miller Fisher/patología , Síndrome de Miller Fisher/fisiopatología , Neuronas Motoras/inmunología , Neuronas Motoras/metabolismo , Neuronas Motoras/patología , Proteínas de Neurofilamentos/metabolismo , Unión Neuromuscular/metabolismo , Unión Neuromuscular/patología , Unión Neuromuscular/fisiopatología , Fosforilación/efectos de los fármacos , Células de Schwann/patología , Células de Schwann/ultraestructura , Transmisión Sináptica/efectos de los fármacos , Transmisión Sináptica/inmunología , Tubulina (Proteína)/metabolismoAsunto(s)
Ácido Aspártico/análogos & derivados , Ácido Aspártico/metabolismo , Encéfalo/metabolismo , Neuronas/metabolismo , Encéfalo/anatomía & histología , Encéfalo/fisiopatología , Encefalopatías Metabólicas/fisiopatología , Preescolar , Discapacidades del Desarrollo/fisiopatología , Humanos , Espectroscopía de Resonancia MagnéticaRESUMEN
Axonal degeneration has been proposed as a cause of irreversible neurological disability in multiple sclerosis (MS) patients. The purpose of this study was to quantify axonal loss in spinal cord lesions from 5 paralyzed (Expanded Disability Status Scale score > or =7.5) MS patients and to determine if axonal number or volume correlated with levels of the neuronal marker N-acetyl aspartate (NAA). Axonal loss in MS lesions ranged from 45 to 84% and averaged 68%. NAA levels were significantly reduced (>50%) in cross sections of spinal cords containing MS lesions. Reduced NAA correlated with reduced axonal numbers within lesion areas. In addition, NAA levels per axonal volume were significantly reduced in demyelinated axons (42%) and in myelinated axons in normal-appearing white matter (30%). The data support axonal loss as a major cause of irreversible neurological disability in paralyzed MS patients and indicate that reduced NAA as measured by magnetic resonance spectroscopy can reflect axonal loss and reduced NAA levels in demyelinated and myelinated axons.
Asunto(s)
Ácido Aspártico/análogos & derivados , Ácido Aspártico/análisis , Axones/patología , Esclerosis Múltiple/patología , Esclerosis Múltiple/fisiopatología , Médula Espinal/patología , Adulto , Anciano , Anciano de 80 o más Años , Enfermedad Crónica , Evaluación de la Discapacidad , Femenino , Humanos , Masculino , Persona de Mediana EdadAsunto(s)
Axones/fisiología , Moléculas de Adhesión Celular/metabolismo , Uniones Intercelulares/fisiología , Factores de Crecimiento Nervioso/metabolismo , Neuroglía/fisiología , Nódulos de Ranvier/fisiología , Axones/ultraestructura , Uniones Intercelulares/ultraestructura , Modelos Biológicos , Neuroglía/ultraestructura , Nódulos de Ranvier/ultraestructuraRESUMEN
Multiple sclerosis (MS) is characterized by multifocal loss of myelin, oligodendrocytes, and axons. Potential MS therapies include enhancement of remyelination by transplantation or manipulation of endogenous oligodendrocyte progenitor cells. Characteristics of endogenous oligodendrocyte progenitors in normal human brain and in MS lesions have not been studied extensively. This report describes the distribution of cells in sections from normal adult human brain and MS lesions by using antibodies directed against NG2, an integral membrane chondroitin sulfate proteoglycan expressed by oligodendrocyte progenitor cells. Stellate-shaped NG2-positive cells were detected in the white and gray matter of normal adult human brain and appeared as abundant as, but distinct from, astrocytes, oligodendrocytes, and microglia. Stellate-shaped or elongated NG2-positive cells also were detected in chronic MS lesions. A subpopulation of the elongated NG2-positive cells expressed the putative apoptotic signaling molecule p75(NTR). TUNEL-positive cells in three active, nine chronic active, and four chronic inactive lesions, however, were p75(NTR)-negative. These studies identify cells with phenotypic markers of endogenous oligodendrocyte progenitors in the mature human CNS and suggest that functional subpopulations of NG2-positive cells exist in MS lesions. Endogenous oligodendrocyte progenitor cells may represent a viable target for future therapies intended to enhance remyelination in MS patients.
Asunto(s)
Antígenos/análisis , Encéfalo/patología , Esclerosis Múltiple/patología , Oligodendroglía/patología , Proteoglicanos/análisis , Células Madre/patología , Adulto , Edad de Inicio , Anciano , Apoptosis , Encéfalo/citología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oligodendroglía/citología , Receptor alfa de Factor de Crecimiento Derivado de Plaquetas/análisis , Receptores de Factor de Crecimiento Nervioso/análisis , Valores de ReferenciaRESUMEN
This report investigated mechanisms responsible for failed Schwann cell myelination in mice that overexpress P(0) (P(0)(tg)), the major structural protein of PNS myelin. Quantitative ultrastructural immunocytochemistry established that P(0) protein was mistargeted to abaxonal, periaxonal, and mesaxon membranes in P(0)(tg) Schwann cells with arrested myelination. The extracellular leaflets of P(0)-containing mesaxon membranes were closely apposed with periodicities of compact myelin. The myelin-associated glycoprotein was appropriately sorted in the Golgi apparatus and targeted to periaxonal membranes. In adult mice, occasional Schwann cells myelinated axons possibly with the aid of endocytic removal of mistargeted P(0). These results indicate that P(0) gene multiplication causes P(0) mistargeting to mesaxon membranes, and through obligate P(0) homophilic adhesion, renders these dynamic membranes inert and halts myelination.
Asunto(s)
Proteína P0 de la Mielina/metabolismo , Vaina de Mielina/metabolismo , Células de Schwann/metabolismo , Envejecimiento , Animales , Axones/metabolismo , Axones/ultraestructura , Membrana Celular/metabolismo , Membrana Celular/ultraestructura , Endosomas/metabolismo , Endosomas/ultraestructura , Amplificación de Genes , Aparato de Golgi/metabolismo , Aparato de Golgi/ultraestructura , Inmunohistoquímica , Ratones , Ratones Transgénicos , Microscopía Electrónica , Proteína P0 de la Mielina/genética , Vaina de Mielina/ultraestructura , Glicoproteína Asociada a Mielina/metabolismo , ARN Mensajero/biosíntesis , Células de Schwann/citología , Células de Schwann/ultraestructura , Nervio Ciático/metabolismo , Nervio Ciático/ultraestructura , Raíces Nerviosas Espinales/metabolismo , Raíces Nerviosas Espinales/ultraestructuraRESUMEN
We show that normal peripheral nerve myelination depends on strict dosage of the most abundantly expressed myelin gene, myelin protein zero (Mpz). Transgenic mice containing extra copies of Mpz manifested a dose-dependent, dysmyelinating neuropathy, ranging from transient perinatal hypomyelination to arrested myelination and impaired sorting of axons by Schwann cells. Myelination was restored by breeding the transgene into the Mpz-null background, demonstrating that dysmyelination does not result from a structural alteration or Schwann cell-extrinsic effect of the transgenic P(0) glycoprotein. Mpz mRNA overexpression ranged from 30-700%, whereas an increased level of P(0) protein was detected only in nerves of low copy-number animals. Breeding experiments placed the threshold for dysmyelination between 30 and 80% Mpz overexpression. These data reveal new points in nerve development at which Schwann cells are susceptible to increased gene dosage, and suggest a novel basis for hereditary neuropathy.
Asunto(s)
Enfermedades Desmielinizantes/congénito , Dosificación de Gen , Proteína P0 de la Mielina/biosíntesis , Proteína P0 de la Mielina/genética , Enfermedades del Sistema Nervioso Periférico/congénito , Animales , Western Blotting , Enfermedades Desmielinizantes/genética , Enfermedades Desmielinizantes/metabolismo , Enfermedades Desmielinizantes/patología , Regulación de la Expresión Génica , Ratones , Ratones Endogámicos BALB C , Ratones Transgénicos , Proteína Básica de Mielina/biosíntesis , Proteína Básica de Mielina/genética , Proteínas de la Mielina/biosíntesis , Proteínas de la Mielina/genética , Especificidad de Órganos , Enfermedades del Sistema Nervioso Periférico/genética , Enfermedades del Sistema Nervioso Periférico/metabolismo , Enfermedades del Sistema Nervioso Periférico/patología , Isoformas de Proteínas/biosíntesis , Isoformas de Proteínas/genética , ARN Mensajero/biosíntesis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células de Schwann/metabolismo , Células de Schwann/ultraestructura , Nervio Ciático/metabolismo , Nervio Ciático/ultraestructuraRESUMEN
We describe a major glial cell population in the central nervous system (CNS) that can be identified by the expression of 2 cell surface molecules, the NG2 proteoglycan and the alpha receptor for platelet-derived growth factor (PDGF alphaR). In vitro and in the developing brain in vivo, NG2 and PDGF alphaR are expressed on oligodendrocyte progenitor cells but are down-regulated as the progenitor cells differentiate into mature oligodendrocytes. In the mature CNS, numerous NG2+/PDGF alphaR+ cells with extensive arborization of their cell processes are found ubiquitously long after oligodendrocytes are generated. NG2+ cells in the mature CNS do not express antigens specific to mature oligodendrocytes, astrocytes, microglia, or neurons, suggesting that they are a novel population of glial cells. Recently NG2+ cells in the adult CNS have been shown to undergo proliferation and morphological changes in response to a variety of stimuli, such as demyelination and inflammation, suggesting that they are dynamic cells capable of responding to changes in the environment. Furthermore, high levels of NG2+ and PDGF alphaR are expressed on oligodendroglioma cells, raising the possibility that the NG2+/PDGF alphaR+ cells in the mature CNS contribute to glial neoplasm.
Asunto(s)
Antígenos/análisis , Encéfalo/citología , Neuroglía/química , Neuroglía/citología , Proteoglicanos/análisis , Factores de Edad , Animales , Encéfalo/patología , Encefalopatías/patología , Ratones , Ratones JimpyRESUMEN
In this review, data is summarized supporting the hypothesis that axonal loss is a major pathologic process responsible for irreversible neurologic disability in patients with multiple sclerosis. Pathologic studies implicate inflammatory demyelination as a principal cause of axonal transection and subsequent axonal degeneration. Axonal degeneration caused by chronic demyelination in the absence of active inflammation may also contribute to progressive disability in the later stages of the disease. Studies using magnetic resonance spectroscopy suggest that axonal loss begins at the onset of the disease, and studies using magnetic resonance imaging have documented brain atrophy in the earliest stages of multiple sclerosis. Brain atrophy increases during the relapsing-remitting disease stage without concurrent disability progression. This suggests that compensatory mechanisms maintain neurologic function, despite progressive brain tissue loss during the early stages of the disease. Beyond a threshold, however, further axonal loss leads to continuously progressive neurologic disability. We hypothesize that the rate and extent of axonal loss during relapsing-remitting multiple sclerosis determines when a patient enters the secondary progressive stage of the disease. This view of disease pathogenesis has several important implications. First, surrogate markers of axonal loss are needed to monitor the disease process for patient care and for clinical trials. We propose brain parenchymal fraction, a precise measure of whole-brain atrophy, as an attractive candidate for this purpose. Second, disease-modifying therapy should be used early in multiple sclerosis patients, before extensive axonal loss has occurred. Third, neuroprotective drugs should be tested in combination with anti-inflammatory drugs in multiple sclerosis patients. Finally, studies of the time course of axonal loss, and its mechanisms are critical for effective therapeutic intervention.